Cancer Research and Treatment

Case Reports

Long-Term Survival after T-cell Lymphoblastic Lymphoma Treated with One Cycle of Hyper-CVAD Regimen: Il Hwan Ryu, In Sung Cho, Ah Jeong Ryu, Min Gyu Kim, Jae Woong Jeon, Joo Seok Kim, Jae Joon Lee, Ji Wook Choi, Dong Wook Kang; Cancer Res Treat. 2015;47(1):115-119. Published online August 25, 2014; DOI: https://doi.org/10.4143/crt.2013.122

T-lymphoblastic lymphoma (T-LBL) is a rare form of aggressive non-Hodgkin’s lymphoma. The standard approach for management of T-LBL involves intensive multiagent chemotherapy regimens for induction and consolidation phases with central nervous system prophylaxis and a maintenance phase lasting 12-18 months. We report on a case of long-term survival after one cycle of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) and high-dose methotrexate. A 30-year-old woman diagnosed with T-LBL with a large mediastinal mass underwent one cycle of hyper-CVAD. Four days after the start of treatment, the mediastinal mass was markedly reduced. Treatment continued with one cycle of consolidation chemotherapy, comprising high-dose methotrexate and high-dose cytarabine. The patient then refused all further chemotherapeutic treatment. Seven years have passed without relapse.

Citations

Citations to this article as recorded by

An aberrant presentation of non-hodgkin’s lymphoma as pus: A curious journey
Mayur Devraj, Chaitanya Kappagantu, Sushma Dugad, Ravidra Shinde, Komal Shah
IP Indian Journal of Immunology and Respiratory Medicine.2023; 7(4): 173. CrossRef
The Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios as New Prognostic Factors in Hematological Malignancies – A Narrative Review

Paulina Stefaniuk, Agnieszka Szymczyk, Monika Podhorecka
Cancer Management and Research.2020; Volume 12: 2961. CrossRef
T-cell lymphoblastic lymphoma involving the ocular adnexa: report of two cases and review of the current literature
Lucy Sun, Alan H. Friedman, Rand Rodgers, Matthew Schear, Giovanni Greaves, Kathryn B. Freidl
Orbit.2019; 38(5): 412. CrossRef
Effectiveness of modified hyper‐CVAD chemotherapy regimen in the treatment of adult acute lymphoblastic leukemia: a retrospective experience
Hasan Jalaeikhoo, Mohsen Rajaeinejad, Manoutchehr Keyhani, Mohammad Zokaasadi, Mohammad Mehdi Dehghani Firoozabadi
Cancer Medicine.2018; 7(3): 594. CrossRef

16,650 View
98 Download
3 Web of Science
4 Crossref

Hepatic Metastases of Gastric Adenocarcinoma Showing Metabolic Remission on FDG-PET Despite an Increase in Size on CT: So Young Yoon, Sung-Yong Kim, Yo-Han Cho, Hyun Woo Chung, Young So, Hong M Lee; Cancer Res Treat. 2009;41(2):100-103. Published online June 30, 2009; DOI: https://doi.org/10.4143/crt.2009.41.2.100

Abstract PDF PubReader ePub

We report a gastric adenocarcinoma patient with liver metastases. The metastases showed progression on computed tomography (CT), but this was not true progression in terms of metabolic activity according to ¹⁸F-fluorodeoxyglucose positron emission tomography (FDG-PET). Discordance between size criteria and metabolic criteria has been reported in liver gastrointestinal stromal tumors, hepatomas, and renal cell carcinomas after dramatic responses with targeted therapies such as imatinib, sorafenib, and sunitinib (1-6). However, this discordance has been rarely reported in liver metastases of gastric adenocarcinoma when treated with conventional chemotherapy.

Citations

Citations to this article as recorded by

Phase II trial evaluating the efficacy of sorafenib (BAY 43‐9006) and correlating early fluorodeoxyglucose positron emission tomography–CT response to outcome in patients with recurrent and/or metastatic head and neck cancer
Yassine Lalami, Camillo Garcia, Patrick Flamen, Lieveke Ameye, Marianne Paesmans, Ahmad Awada
Head & Neck.2016; 38(3): 347. CrossRef
A Case of Long-Term Complete Remission of Advanced Gastric Adenocarcinoma with Liver Metastasis
Ch'angbum Rim, Jung-Ae Lee, Soojung Gong, Dong Wook Kang, Heebum Yang, Hyun Young Han, Nae Yu Kim
Journal of Gastric Cancer.2016; 16(2): 115. CrossRef
PRELIMINARY EVALUATION OF SERIAL 18FDG‐PET/CT TO ASSESS RESPONSE TO TOCERANIB PHOSPHATE THERAPY IN CANINE CANCER
Amy K. LeBlanc, Ashley N. Miller, Gina D. Galyon, Tamberlyn D. Moyers, Misty J. Long, Alan C. Stuckey, Jonathan S. Wall, Federica Morandi
Veterinary Radiology & Ultrasound.2012; 53(3): 348. CrossRef
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
Yung-Jue Bang, Yoon-Koo Kang, Won K. Kang, Narikazu Boku, Hyun C. Chung, Jen-Shi Chen, Toshihiko Doi, Yan Sun, Lin Shen, Shukui Qin, Wai-Tong Ng, Jennifer M. Tursi, Maria J. Lechuga, Dongrui Ray Lu, Ana Ruiz-Garcia, Alberto Sobrero
Investigational New Drugs.2011; 29(6): 1449. CrossRef

8,551 View
57 Download
4 Crossref

Original Article

Treatment of Childhood Acute Lymphoblastic Leukemia Diagnosed Jan . , 1978 Through Dec . , 1987 : Comparison between Standard - Risk and High - Risk Groups: Soon Ki Kim, Hee Young Shin, Hyo Seop Ahn; J Korean Cancer Assoc. 1990;22(3):539-549.

Abstract PDF: Of 328 children who were diagnosed as acute lymphoblastic leukemia at the Department of Pediatrics. Seoul National University Hospital from Jan., 1978 through Dec., 1987, 211 patients above one year af age were evaluable for induction chemotherapy. The leukemias were classified as standard risk (SR), comparison group (who had high-risk prognostic factors, but had been treated with standard regimen), or high- risk (HR) leukemia according to the prognostic criteria at diagnosis. Three regimens were compared and the results were as follows. 1) The complete remission (CR) rate was 97.1%(133/137), 81.0%(34/42) and 90.6%(29/32) in SR, comparison group. and HR group, respectively. And significant difference in the CR rate was seen between SR group and comparison group (p= 0.0001). 2) Of the patients remained in remission follow-up of each group showed 56.8% 5-yr disease-free survival (DFS)(+-5.9%, median follow-up 30 mo) in SR, 35.5% (+-9.1%, median 24 mo) in comparison group, and 76.0%(+- 8.5%, median 24 mo) in HR group. And significant difference in the 5yr-DFS rate were observed be(ween SR and comparison group (P = 0.007), between HR and comparison group (p = 0.002), respectively. 3) Induction failure was due to infection (n=2) bleeding (n=1) or uric acid nephropathy (n= 1) in SR drug resistance (n=3), infection (n=2), bleeding (n=2), or combind infection and bleeding (n=1) in comparison group, and bleeding (n=2) or infection (n= 1) in HR. Of the patients who were on maintenance chemotherapy in complete remission, 11 died due to infection: menigitis or meningoencephalitis (n=4), disseminated varicella (n=3), Pneumocystis carinii pneumonia (n=2), and sepsis (n=2). 4) In SR group, 29 patients experienced relapse: BM(n=18), CNS(n=3), BM and CNS(n=4), and testes (n=4). Two- third (n = 19) of them relapsed between 6mo to 2yr after initial remission. In comparison graup, 20 relapsed: BM (n= 10), CNS(n=2), BM and CNS (n=3), testes (n=4), and testes and CNS(n =1), Mostly they relapsed within the first 2 years after remission. In HR group, all patients (BM 3 and CNS 1) experienced relapse from 1 yr to 1 1/2 yr after initial remission.

2,228 View
15 Download

First
Prev
Page of 1
Next
Last

Search